TATTON phase Ib expansion cohort: Osimertinib plus savolitinib for patients (pts) with EGFR-mutant, MET-amplified NSCLC after progression on prior third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) Meeting Abstract
| Authors: | Sequist, L. V.; Lee, J. S.; Han, J. Y.; Su, W. C.; Yang, J. C. H.; Yu, H.; Ottesen, L. H.; Verheijen, R. B.; Mellemgaard, A.; Wessen, J.; Oxnard, G.; Cho, B. C. |
| Abstract Title: | TATTON phase Ib expansion cohort: Osimertinib plus savolitinib for patients (pts) with EGFR-mutant, MET-amplified NSCLC after progression on prior third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) |
| Meeting Title: | 110th Annual Meeting of the American Association for Cancer Research (AACR) |
| Journal Title: | Cancer Research |
| Volume: | 79 |
| Issue: | 13 Suppl. |
| Meeting Dates: | 2019 Mar 29-Apr 3 |
| Meeting Location: | Atlanta, GA |
| ISSN: | 0008-5472 |
| Publisher: | American Association for Cancer Research |
| Date Published: | 2019-07-01 |
| Language: | English |
| ACCESSION: | WOS:000488129900029 |
| DOI: | 10.1158/1538-7445.Am2019-ct033 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: CT033 -- Source: Wos |
